Remove Angina Remove Myocardial Infarction Remove Sudden Cardiac Death
article thumbnail

Sildenafils effectiveness in the primary coronary slow flow phenomenon: a pilot randomised controlled clinical trial

Open Heart

Background On the one hand, the primary coronary slow flow phenomenon (CSFP) can cause recurrence of chest pain, prompting medical examinations and further healthcare costs, while on the other hand, it can lead to myocardial infarction, ventricular arrhythmia and sudden cardiac death.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heart attack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4

article thumbnail

The “open data” movement runs aground on FOURIER

Dr. Anish Koka

The TIMI (Thrombolysis in Myocardial Infarction) Study Group is a Division of Cardiovascular Medicine at the esteemed Brigham and Women’s Hospital and Harvard Medical School. Importantly, there was no difference in cardiovascular death or death from any cause.

article thumbnail

Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine

Evidence supports the use of TXL plus WM for reducing angina frequency [SMD 2.50, 95% CI (3.53, 1.48)], improving seattle angina questionnaire scores (P<0.05), decreasing nitroglycerin dose [SMD 1.63, 95% CI (2.26, 1.00)], and shortening angina duration [MD 1.50min/once, 95% CI (1.98, 1.02)].